Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 25 studies | 29% ± 13% | |
| glutamatergic neuron | 12 studies | 39% ± 26% | |
| astrocyte | 12 studies | 35% ± 16% | |
| macrophage | 12 studies | 31% ± 14% | |
| oligodendrocyte precursor cell | 12 studies | 32% ± 13% | |
| oligodendrocyte | 12 studies | 31% ± 11% | |
| microglial cell | 11 studies | 32% ± 10% | |
| pericyte | 10 studies | 24% ± 10% | |
| fibroblast | 10 studies | 29% ± 10% | |
| GABAergic neuron | 9 studies | 41% ± 22% | |
| B cell | 9 studies | 23% ± 9% | |
| naive B cell | 8 studies | 18% ± 2% | |
| neuron | 7 studies | 38% ± 17% | |
| plasmacytoid dendritic cell | 7 studies | 22% ± 5% | |
| myeloid cell | 7 studies | 25% ± 6% | |
| adipocyte | 7 studies | 25% ± 6% | |
| smooth muscle cell | 7 studies | 25% ± 7% | |
| interneuron | 6 studies | 43% ± 23% | |
| epithelial cell | 6 studies | 42% ± 20% | |
| basal cell | 6 studies | 33% ± 17% | |
| club cell | 6 studies | 29% ± 11% | |
| retina horizontal cell | 6 studies | 21% ± 4% | |
| retinal cone cell | 6 studies | 25% ± 7% | |
| dendritic cell | 6 studies | 24% ± 2% | |
| ciliated cell | 6 studies | 29% ± 10% | |
| Mueller cell | 6 studies | 25% ± 6% | |
| endothelial cell of lymphatic vessel | 6 studies | 30% ± 10% | |
| type II pneumocyte | 6 studies | 39% ± 12% | |
| mast cell | 5 studies | 24% ± 5% | |
| monocyte | 5 studies | 27% ± 8% | |
| type I pneumocyte | 5 studies | 36% ± 10% | |
| granule cell | 4 studies | 29% ± 7% | |
| retinal bipolar neuron | 4 studies | 25% ± 3% | |
| cardiac muscle cell | 4 studies | 33% ± 3% | |
| mesothelial cell | 4 studies | 33% ± 8% | |
| lymphocyte | 4 studies | 29% ± 9% | |
| retinal rod cell | 4 studies | 24% ± 3% | |
| abnormal cell | 4 studies | 26% ± 14% | |
| GABAergic interneuron | 3 studies | 28% ± 3% | |
| glial cell | 3 studies | 20% ± 3% | |
| retinal ganglion cell | 3 studies | 23% ± 0% | |
| precursor B cell | 3 studies | 18% ± 1% | |
| plasma cell | 3 studies | 26% ± 5% | |
| immature B cell | 3 studies | 19% ± 3% | |
| vein endothelial cell | 3 studies | 28% ± 14% | |
| ON-bipolar cell | 3 studies | 20% ± 3% | |
| glycinergic amacrine cell | 3 studies | 19% ± 1% | |
| rod bipolar cell | 3 studies | 47% ± 6% | |
| cholangiocyte | 3 studies | 49% ± 16% | |
| hepatocyte | 3 studies | 40% ± 23% | |
| neural progenitor cell | 3 studies | 22% ± 3% | |
| ependymal cell | 3 studies | 32% ± 15% | |
| T cell | 3 studies | 24% ± 1% | |
| alveolar macrophage | 3 studies | 32% ± 10% | |
| natural killer cell | 3 studies | 20% ± 3% | |
| respiratory goblet cell | 3 studies | 34% ± 11% | |
| goblet cell | 3 studies | 39% ± 30% | |
| transit amplifying cell | 3 studies | 34% ± 26% | |
| mural cell | 3 studies | 33% ± 10% | |
| mucus secreting cell | 3 studies | 30% ± 2% | |
| regulatory T cell | 3 studies | 16% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 5746.86 | 2642 / 2642 | 100% | 79.41 | 705 / 705 |
| breast | 100% | 3033.37 | 459 / 459 | 100% | 41.94 | 1114 / 1118 |
| prostate | 100% | 2939.90 | 245 / 245 | 100% | 38.93 | 500 / 502 |
| esophagus | 100% | 3575.07 | 1445 / 1445 | 99% | 27.84 | 182 / 183 |
| ovary | 100% | 3393.06 | 180 / 180 | 99% | 28.23 | 427 / 430 |
| intestine | 100% | 2882.12 | 966 / 966 | 99% | 25.41 | 523 / 527 |
| lung | 100% | 3589.02 | 577 / 578 | 99% | 31.63 | 1148 / 1155 |
| stomach | 100% | 3245.64 | 359 / 359 | 99% | 25.76 | 283 / 286 |
| thymus | 100% | 2798.83 | 652 / 653 | 99% | 35.01 | 599 / 605 |
| uterus | 100% | 3832.55 | 170 / 170 | 99% | 29.05 | 453 / 459 |
| pancreas | 100% | 2401.24 | 328 / 328 | 98% | 34.65 | 175 / 178 |
| skin | 100% | 3343.99 | 1808 / 1809 | 98% | 40.77 | 464 / 472 |
| kidney | 100% | 2774.62 | 89 / 89 | 97% | 35.26 | 877 / 901 |
| bladder | 100% | 3318.67 | 21 / 21 | 97% | 23.66 | 490 / 504 |
| adrenal gland | 100% | 3847.58 | 258 / 258 | 97% | 37.74 | 223 / 230 |
| liver | 100% | 1637.22 | 226 / 226 | 97% | 23.99 | 393 / 406 |
| adipose | 100% | 3199.17 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 4410.85 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 26.44 | 29 / 29 |
| muscle | 100% | 3738.76 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2564.79 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 35.33 | 45 / 45 |
| eye | 0% | 0 | 0 / 0 | 99% | 24.05 | 79 / 80 |
| heart | 97% | 3183.95 | 836 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 65% | 1586.10 | 604 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0006470 | Biological process | protein dephosphorylation |
| GO_0000209 | Biological process | protein polyubiquitination |
| GO_0008090 | Biological process | retrograde axonal transport |
| GO_0045862 | Biological process | positive regulation of proteolysis |
| GO_0000132 | Biological process | establishment of mitotic spindle orientation |
| GO_0031648 | Biological process | protein destabilization |
| GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
| GO_0007281 | Biological process | germ cell development |
| GO_0042753 | Biological process | positive regulation of circadian rhythm |
| GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
| GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
| GO_0007097 | Biological process | nuclear migration |
| GO_0048854 | Biological process | brain morphogenesis |
| GO_0016055 | Biological process | Wnt signaling pathway |
| GO_0031023 | Biological process | microtubule organizing center organization |
| GO_0048511 | Biological process | rhythmic process |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0047496 | Biological process | vesicle transport along microtubule |
| GO_0000151 | Cellular component | ubiquitin ligase complex |
| GO_0005813 | Cellular component | centrosome |
| GO_0000776 | Cellular component | kinetochore |
| GO_0043025 | Cellular component | neuronal cell body |
| GO_0005635 | Cellular component | nuclear envelope |
| GO_0043005 | Cellular component | neuron projection |
| GO_0005829 | Cellular component | cytosol |
| GO_0005881 | Cellular component | cytoplasmic microtubule |
| GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
| GO_0005875 | Cellular component | microtubule associated complex |
| GO_1904115 | Cellular component | axon cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
| GO_0051010 | Molecular function | microtubule plus-end binding |
| GO_0070840 | Molecular function | dynein complex binding |
| GO_0046983 | Molecular function | protein dimerization activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FBXW11 |
| Protein name | F-box/WD repeat-containing protein 11 (F-box and WD repeats protein beta-TrCP2) (F-box/WD repeat-containing protein 1B) (Homologous to Slimb protein) (HOS) F-box and WD repeat domain containing 11 |
| Synonyms | FBW1B KIAA0696 BTRCP2 FBXW1B |
| Description | FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins . Probably recognizes and binds to phosphorylated target proteins: the interaction with substrates requires the phosphorylation of the two serine residues in the substrates' destruction motif D-S-G-X(2,3,4)-S . SCF(FBXW11) mediates the ubiquitination of phosphorylated CTNNB1 and participates in Wnt signaling regulation . SCF(FBXW11) plays a key role in NF-kappa-B activation by mediating ubiquitination of phosphorylated NFKBIA, leading to its degradation by the proteasome, thereby allowing the associated NF-kappa-B complex to translocate into the nucleus and to activate transcription . The SCF(FBXW11) complex also regulates NF-kappa-B by mediating ubiquitination of phosphorylated NFKB1: specifically ubiquitinates the p105 form of NFKB1, leading to its degradation . SCF(FBXW11) mediates the ubiquitination of IFNAR1 . SCF(FBXW11) mediates the ubiquitination of CEP68; this is required for centriole separation during mitosis . Involved in the oxidative stress-induced a ubiquitin-mediated decrease in RCAN1 . Mediates the degradation of CDC25A induced by ionizing radiation in cells progressing through S phase and thus may function in the intra-S-phase checkpoint . Has an essential role in the control of the clock-dependent transcription via degradation of phosphorylated PER1 and phosphorylated PER2 . SCF(FBXW11) mediates the ubiquitination of CYTH1, and probably CYTH2 . SCF(FBXW11) acts as a regulator of mTORC1 signaling pathway by catalyzing ubiquitination and subsequent proteasomal degradation of phosphorylated DEPTOR, TFE3 and MITF . .; FUNCTION: (Microbial infection) Target of human immunodeficiency virus type 1 (HIV-1) protein VPU to polyubiquitinate and deplete BST2 from cells and antagonize its antiviral action. . |
| Accessions | ENST00000393802.6 [Q9UKB1-2] ENST00000265094.9 [Q9UKB1-1] ENST00000523843.5 E5RGC1 E5RH92 ENST00000518752.1 ENST00000296933.10 [Q9UKB1-3] ENST00000519693.5 ENST00000517395.6 E5RG78 ENST00000520376.1 Q9UKB1 |